|
Post by newmnkdinvestor on May 14, 2015 21:47:39 GMT -5
Share holder dilution for August debt.
|
|
|
Post by obamayoumama on May 14, 2015 22:19:31 GMT -5
Share holder dilution for August debt. Matt has stated several times that there will be no dilution for the August Debt.
|
|
|
Post by newmnkdinvestor on May 14, 2015 22:33:31 GMT -5
I know but I would like to keep hearing it over and over until its paid!!! ?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 14, 2015 23:10:57 GMT -5
I know but I would like to keep hearing it over and over until its paid!!! ? It's more likely to be refi'd, not paid.
|
|
|
Post by bradleysbest on May 19, 2015 9:03:56 GMT -5
I have a feeling there will be good news announced at the share holder meeting. Just a hunch but I think the TS deal for pain will be announced in detail or some other type of good news (EU application, lines 2-3 are running, etc..). After Matt's terrific presentation in LV maybe I am expecting too much!
|
|
|
Post by suebeeee1 on May 19, 2015 9:11:12 GMT -5
I have a feeling there will be good news announced at the share holder meeting. Just a hunch but I think the TS deal for pain will be announced in detail or some other type of good news (EU application, lines 2-3 are running, etc..). After Matt's terrific presentation in LV maybe I am expecting too much! Too early for a TS deal to be announced. It would be wonderful...... But remember the team we are working with here! Stay grounded. If you don't expect much, you won't be disappointed.
|
|
|
Post by liane on May 19, 2015 9:32:45 GMT -5
Can't announce anything that is material without also announcing to general public through a PR. That said, in 2011, we had a wonderful announcement at 6:30 AM re the Starbucks deal - on the day of the s/h meeting. Set a very good tone for the meeting.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 19, 2015 13:48:22 GMT -5
Can't announce anything that is material without also announcing to general public through a PR. That said, in 2011, we had a wonderful announcement at 6:30 AM re the Starbucks deal - on the day of the s/h meeting. Set a very good tone for the meeting. and what was that?
|
|
|
Post by BD on May 19, 2015 15:05:53 GMT -5
Liane's talking about GMCR... our model for how short squeezes can run!
|
|
|
Post by liane on May 19, 2015 15:32:08 GMT -5
OOPS!
Was typing so fast I neglected the ticker reference.
|
|
|
Post by kc on May 19, 2015 20:06:39 GMT -5
There can always be a pre-market announcement by both companies regarding big news.. Unlikely but it still could happen. That would meet SEC rules. I suspect much of the high volume and share uptick is because anything is possible and shorts are nervous about it.
|
|
|
Post by corpplanner on May 20, 2015 0:42:52 GMT -5
I have a question for this board but don't know if it would be appropriate for the annual mtg. It has to do with the financial implications of the SNY deal and profitability for MNKD.
I've been looking at the wonderful posts regarding the dinner presentations on Afrezza (impressive and thank you for these posts)and it occurred to me that Mannkind might make more money than we realize on the SNY deal. The name of each presentation is "Afrezza: Inhaled Insulin Powder" and we know that the NDA for the powder was transferred to SNY. But, MNKD kept the inhaler device technology (and presumably the patents for the unit dose packaging, as well), which they promote on the MNKD website as one way to partner with MNKD.
So, the question would be: does MNKD split the profits with SNY solely on the inhaled insulin powder and then keep the full cost of the inhaler and as the packager of the "kit" that the patient uses? Or, does the partnership with SNY include the cost of the inhaler and packaging == the "kit" so to speak? The thought behind this question is that if MNKD gets paid in full for the device and then again in full for packaging and then again for the insulin (but only at cost) in the unit dose packaging, which is then supplied to the joint venture as a "kit," that MNKD will make a lot more money on each kit than just the 35% split after "expenses." It would sort of be the difference between being a parts supplier (eg: OEM to a branded mfr) vs. being a full partner in a jv where all assets are tossed into the venture. I don't know if I'm making this question clear so please let me know what you think. The implications, though, for the former scenario would be much more lucrative to MNKD once all mfg lines are up and running.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 20, 2015 1:03:14 GMT -5
I have a question for this board but don't know if it would be appropriate for the annual mtg. It has to do with the financial implications of the SNY deal and profitability for MNKD. I've been looking at the wonderful posts regarding the dinner presentations on Afrezza (impressive and thank you for these posts)and it occurred to me that Mannkind might make more money than we realize on the SNY deal. The name of each presentation is "Afrezza: Inhaled Insulin Powder" and we know that the NDA for the powder was transferred to SNY. But, MNKD kept the inhaler device technology (and presumably the patents for the unit dose packaging, as well), which they promote on the MNKD website as one way to partner with MNKD. So, the question would be: does MNKD split the profits with SNY solely on the inhaled insulin powder and then keep the full cost of the inhaler and as the packager of the "kit" that the patient uses? Or, does the partnership with SNY include the cost of the inhaler and packaging == the "kit" so to speak? The thought behind this question is that if MNKD gets paid in full for the device and then again in full for packaging and then again for the insulin (but only at cost) in the unit dose packaging, which is then supplied to the joint venture as a "kit," that MNKD will make a lot more money on each kit than just the 35% split after "expenses." It would sort of be the difference between being a parts supplier (eg: OEM to a branded mfr) vs. being a full partner in a jv where all assets are tossed into the venture. I don't know if I'm making this question clear so please let me know what you think. The implications, though, for the former scenario would be much more lucrative to MNKD once all mfg lines are up and running. it has been beaten to death on this forum with some great analysis.. to keep it simple - mid 20's royalty
|
|
|
Post by mnholdem on May 20, 2015 7:56:02 GMT -5
corpplanner - welcome, BTW, even though you've been a member since last August - I think we've established that the COGS, for which MannKind gets reimbursed by Sanofi, includes everything in the various packages. Sanofi only pays actual costs. Keep in mind, however, that the Sanofi reimbursement to MannKind results in a positive rather than neutral cash flow for MannKind. Why? Simply because a percentage of the COGS used to bill Sanofi (per the Supplier Agreement) includes inventory that had been prepaid, such as the insulin and quite possibly may even recover some of MannKind's plant/equipment cash, factored in by increasing the equipment burden rates.
Even though production cost is fully reimbursed by Sanofi, 35% of the COGS is then used in calculating (per the Partnership Agreement) the joint profit/loss for Afrezza sales. In the initial quarters, expenses will exceed revenue, primarily because of launch-related marketing costs, resulting in a loss. MannKind's 35% portion of this loss is being entered into the $175 Million Sanofi loan facility (think of it as a revolving loan or line of credit) rather than paid out of cash.
Eventually the revenue will exceed expenses. When that happens, the Agreement states that before MannKind can show a profit, they must first repay past Afrezza expenses, whose previous payments were deferred into the loan facility.
Hopefully by 4Q15 or 1Q16, Afrezza sales will have grown so large that MannKind will be able to pay off the temporary loan and show a positive Earnings/Share, even after factoring in pipeline R&D.
|
|
|
Post by tchalaa on May 20, 2015 12:57:03 GMT -5
Thanks for you who will be attending the shareholder meeting; I wish you could be voice of the voiceless, the shareholder minority overthere. Could you kindly address these points: 1- Regardless from the share quantity, each shareholder want the fiduciary duty (shareholder's value) of the board of directors to be fulfilled 2- Our Investor Relations dept. need to better communicate by addressing, defending, presenting Mannkind evolution, company value 3- What is the stand with the 10 millions equivalent stocks options or warrants which expired on the May 20, 2015 4- Regarding the Pain Management development, how many potential business partner do we have on the side line 5- Can our Dandury plant produce/provide cartridges for the middle-east patients? 6- CONGRATULATIONS FOR ALL THE ACHIEVEMENTS BETWEEN OUR LAST MEETING AND THIS
PLEASE DO IT FOR OUR INTERESTS
|
|